secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001437749-25-035514
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037
----------------------------------------------------------------------------

- USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.
- Patents now granted in US and Korea; applications pending in Europe, Canada, Brazil, China, Israel.
- Acclaim-3 Phase 1/2 trial for ES-SCLC combines REQORSA with Genentech's Tecentriq; Phase 2 expansion to enroll ~50 patients.
- Interim analysis planned after 25th patient reaches 18 weeks; enrollment completion expected first half 2026.
- Acclaim-3 has FDA Fast Track and Orphan Drug designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/0001437749-25-035514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/gnpx20251116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer